S
Surya V. Seshan
Researcher at Cornell University
Publications - 163
Citations - 14254
Surya V. Seshan is an academic researcher from Cornell University. The author has contributed to research in topics: Kidney & Lupus nephritis. The author has an hindex of 46, co-authored 144 publications receiving 11960 citations. Previous affiliations of Surya V. Seshan include Mayo Clinic & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited
Jan J. Weening,Vivette D. D'Agati,Melvin M. Schwartz,Surya V. Seshan,Charles E. Alpers,Gerald B. Appel,James E. Balow,Jan A. Bruijn,Terence Cook,Franco Ferrario,Agnes B. Fogo,Ellen M. Ginzler,Lee A. Hebert,Gary Hill,Prue Hill,J. Charles Jennette,Norella C T Kong,Philippe Lesavre,Michael D. Lockshin,Lai-Meng Looi,Hirofumi Makino,Luiz Antonio Ribeiro de Moura,Michio Nagata +22 more
TL;DR: The main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies.
Journal ArticleDOI
The classification of glomerulonephritis in systemic lupus erythematosus revisited
Jan J. Weening,Vivette D. D'Agati,Melvin M. Schwartz,Surya V. Seshan,Charles E. Alpers,Gerald B. Appel,James E. Balow,Jan A. Bruijn,Terence Cook,Franco Ferrario,Agnes B. Fogo,Ellen M. Ginzler,Lee A. Hebert,Gary Hill,Prue Hill,J. Charles Jennette,Norella C T Kong,Philippe Lesavre,Michael D. Lockshin,Lai-Meng Looi,Hirofumi Makino,Luiz Antonio Ribeiro de Moura,Michio Nagata +22 more
TL;DR: The main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies.
Journal ArticleDOI
Pathologic Classification of Diabetic Nephropathy
Thijs W. Cohen Tervaert,Antien L. Mooyaart,Kerstin Amann,Arthur H. Cohen,H. Terence Cook,Cinthia B. Drachenberg,Franco Ferrario,Agnes B. Fogo,Mark Haas,Emile de Heer,Kensuke Joh,Laure Hélène Noël,Jai Radhakrishnan,Surya V. Seshan,Ingeborg M. Bajema,Jan A. Bruijn +15 more
TL;DR: A consensus classification combining type1 and type 2 diabetic nephropathies is developed that would be easy to use internationally in clinical practice and a good interobserver reproducibility for the four classes of DN was shown.
Journal ArticleDOI
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.
Lorraine C. Racusen,Robert B. Colvin,Kim Solez,Michael J. Mihatsch,Philip F. Halloran,Patricia Campbell,Michael Cecka,Jean Pierre Cosyns,Anthony J. Demetris,Michael C. Fishbein,Agnes B. Fogo,Peter N. Furness,Ian W. Gibson,Denis Glotz,Pekka Häyry,Lawrence Hunsickern,Michael Kashgarian,Ronald H. Kerman,Alex J. Magil,Robert A. Montgomery,Kunio Morozumi,Volker Nickeleit,Parmjeet Randhawa,Heinz Regele,Daniel Serón,Surya V. Seshan,Stale Sund,Kiril Trpkov +27 more
TL;DR: This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001, to be revisited as additional data accumulate in this important area of renal transplantation.
Journal ArticleDOI
Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups
Banu Sis,Michael Mengel,Mark Haas,Robert B. Colvin,Philip F. Halloran,Lorraine C. Racusen,Kim Solez,William M. Baldwin,Erika Bracamonte,V. Broecker,Fernando G. Cosio,Anthony J. Demetris,Cinthia B. Drachenberg,Gunilla Einecke,James M. Gloor,Denis Glotz,Edward S. Kraus,Christophe Legendre,Helen Liapis,Roslyn B. Mannon,Brian J. Nankivell,Volker Nickeleit,John C. Papadimitriou,Parmjeet Randhawa,Heinz Regele,Karine Renaudin,E. R. Rodriguez,Daniel Serón,Surya V. Seshan,Manikkam Suthanthiran,Barbara A. Wasowska,Andrea A. Zachary,A. Zeevi +32 more
TL;DR: The willingness of the Banff process to adapt continuously in response to new research and improve potential weaknesses, led to the implementation of six working groups on the following areas: isolated v‐lesion, fibrosis scoring, glomerular lesions, molecular pathology, polyomavirus nephropathy and quality assurance.